Canadian biopharma Medicago Inc. clinched a strategic alliance with Japan's Mitsubishi Tanabe Pharma Corp. (MTPC) by executing a master research collaboration agreement to develop and commercialize at least three vaccines using its virus-like particle (VLP) technology.